{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:50:23Z","timestamp":1792000223505,"version":"4.4.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02212-x","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T13:14:29Z","timestamp":1758028469000},"page":"1337-1362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-6174","authenticated-orcid":false,"given":"Leah","family":"Zuroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1327-6722","authenticated-orcid":false,"given":"Vista","family":"Farkhondeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-8800","authenticated-orcid":false,"given":"Riley","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-3066","authenticated-orcid":false,"given":"Ari J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"10","key":"2212_CR1","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w. (in Eng).","journal-title":"J Neurol"},{"issue":"4","key":"2212_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210142","volume":"104","author":"JJ Cerqueira","year":"2025","unstructured":"Cerqueira JJ, Berthele A, Cree BAC, et al. Long-term treatment with ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension. Neurology. 2025;104(4): e210142. https:\/\/doi.org\/10.1212\/wnl.0000000000210142. (in Eng).","journal-title":"Neurology"},{"issue":"9","key":"2212_CR3","doi-asserted-by":"publisher","first-page":"awac016","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):awac016. https:\/\/doi.org\/10.1093\/brain\/awac016.","journal-title":"Brain"},{"issue":"5","key":"2212_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"SO California","year":"2019","unstructured":"California SO, Cree BAC, Hollenbach JA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653\u201366. https:\/\/doi.org\/10.1002\/ana.25463.","journal-title":"Ann Neurol"},{"issue":"8","key":"2212_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s1474-4422(20)30140-x","volume":"19","author":"C Lubetzki","year":"2020","unstructured":"Lubetzki C, Zalc B, Williams A, et al. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020;19(8):678\u201388. https:\/\/doi.org\/10.1016\/s1474-4422(20)30140-x.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2212_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrd.2017.115","volume":"16","author":"JR Plemel","year":"2017","unstructured":"Plemel JR, Liu W-Q, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nat Rev Drug Discov. 2017;16(9):617\u201334. https:\/\/doi.org\/10.1038\/nrd.2017.115.","journal-title":"Nat Rev Drug Discov"},{"issue":"6181","key":"2212_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.1249766","volume":"344","author":"GS Tomassy","year":"2014","unstructured":"Tomassy GS, Berger DR, Chen HH, et al. Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex. Science. 2014;344(6181):319\u201324. https:\/\/doi.org\/10.1126\/science.1249766. (in Eng).","journal-title":"Science"},{"issue":"10111","key":"2212_CR8","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/s0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(17)32346-2.","journal-title":"Lancet"},{"issue":"7745","key":"2212_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-018-0842-3","volume":"566","author":"MSY Yeung","year":"2019","unstructured":"Yeung MSY, Djelloul M, Steiner E, et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019;566(7745):538\u201342. https:\/\/doi.org\/10.1038\/s41586-018-0842-3.","journal-title":"Nature"},{"key":"2212_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041371","author":"RJM Franklin","year":"2024","unstructured":"Franklin RJM, Bodini B, Goldman SA. Remyelination in the central nervous system. Cold Spring Harb Perspect Biol. 2024. https:\/\/doi.org\/10.1101\/cshperspect.a041371. (in Eng).","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"50","key":"2212_CR11","doi-asserted-by":"publisher","first-page":"E11807","DOI":"10.1073\/pnas.1808064115","volume":"115","author":"ID Duncan","year":"2018","unstructured":"Duncan ID, Radcliff AB, Heidari M, et al. The adult oligodendrocyte can participate in remyelination. Proc Natl Acad Sci USA. 2018;115(50):E11807\u201316. https:\/\/doi.org\/10.1073\/pnas.1808064115.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2212_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/archneur.60.8.1073","volume":"60","author":"F Barkhof","year":"2003","unstructured":"Barkhof F, Br\u00fcck W, Groot CJA, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003;60(8):1073\u201381. https:\/\/doi.org\/10.1001\/archneur.60.8.1073.","journal-title":"Arch Neurol"},{"issue":"12","key":"2212_CR13","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/brain\/awl217","volume":"129","author":"P Patrikios","year":"2006","unstructured":"Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129(12):3165\u201372. https:\/\/doi.org\/10.1093\/brain\/awl217.","journal-title":"Brain"},{"issue":"10","key":"2212_CR14","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/awq250","volume":"133","author":"S Bramow","year":"2010","unstructured":"Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133(10):2983\u201398. https:\/\/doi.org\/10.1093\/brain\/awq250.","journal-title":"Brain"},{"issue":"2","key":"2212_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ana.410330203","volume":"33","author":"JW Prineas","year":"1993","unstructured":"Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions: remyelination of nascent lesions. Ann Neurol. 1993;33(2):137\u201351. https:\/\/doi.org\/10.1002\/ana.410330203.","journal-title":"Ann Neurol"},{"issue":"45","key":"2212_CR16","doi-asserted-by":"publisher","first-page":"E9685","DOI":"10.1073\/pnas.1714183114","volume":"114","author":"ID Duncan","year":"2017","unstructured":"Duncan ID, Marik RL, Broman AT, et al. Thin myelin sheaths as the hallmark of remyelination persist over time and preserve axon function. Proc Natl Acad Sci USA. 2017;114(45):E9685\u201391. https:\/\/doi.org\/10.1073\/pnas.1714183114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2212_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710\u201321. https:\/\/doi.org\/10.1002\/ana.24497.","journal-title":"Ann Neurol"},{"issue":"22","key":"2212_CR18","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/wnl.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt T, Antel J, K\u00f6nig FB, et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009;72(22):1914\u201321. https:\/\/doi.org\/10.1212\/wnl.0b013e3181a8260a.","journal-title":"Neurology"},{"issue":"3","key":"2212_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-020-02189-9","volume":"140","author":"K He\u00df","year":"2020","unstructured":"He\u00df K, Starost L, Kieran NW, et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol. 2020;140(3):359\u201375. https:\/\/doi.org\/10.1007\/s00401-020-02189-9.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"2212_CR20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/brain\/awn096","volume":"131","author":"T Kuhlmann","year":"2008","unstructured":"Kuhlmann T, Miron V, Cui Q, et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008;131(7):1749\u201358. https:\/\/doi.org\/10.1093\/brain\/awn096.","journal-title":"Brain"},{"issue":"6","key":"2212_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.23693","volume":"72","author":"A Chang","year":"2012","unstructured":"Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol. 2012;72(6):918\u201326. https:\/\/doi.org\/10.1002\/ana.23693.","journal-title":"Ann Neurol"},{"issue":"8","key":"2212_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","volume":"20","author":"F Mei","year":"2014","unstructured":"Mei F, Fancy SPJ, Shen Y-AA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20(8):954\u201360. https:\/\/doi.org\/10.1038\/nm.3618.","journal-title":"Nat Med"},{"issue":"7555","key":"2212_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature14335","volume":"522","author":"FJ Najm","year":"2015","unstructured":"Najm FJ, Madhavan M, Zaremba A, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522(7555):216\u201320. https:\/\/doi.org\/10.1038\/nature14335.","journal-title":"Nature"},{"issue":"30","key":"2212_CR24","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1523\/jneurosci.1493-16.2016","volume":"36","author":"F Mei","year":"2016","unstructured":"Mei F, Mayoral SR, Nobuta H, et al. Identification of the Kappa-opioid receptor as a therapeutic target for oligodendrocyte remyelination. J Neurosci. 2016;36(30):7925\u201335. https:\/\/doi.org\/10.1523\/jneurosci.1493-16.2016.","journal-title":"J Neurosci"},{"issue":"9","key":"2212_CR25","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/brain\/awf216","volume":"125","author":"P Charles","year":"2002","unstructured":"Charles P, Reynolds R, Seilhean D, et al. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain. 2002;125(9):1972\u20139. https:\/\/doi.org\/10.1093\/brain\/awf216.","journal-title":"Brain"},{"issue":"9","key":"2212_CR26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/nm1279","volume":"11","author":"SA Back","year":"2005","unstructured":"Back SA, Tuohy TMF, Chen H, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med. 2005;11(9):966\u201372. https:\/\/doi.org\/10.1038\/nm1279.","journal-title":"Nat Med"},{"issue":"3","key":"2212_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11064-023-04064-x","volume":"49","author":"R AlRuwaili","year":"2024","unstructured":"AlRuwaili R, Al-Kuraishy HM, Al-Gareeb AI, et al. The possible role of brain-derived neurotrophic factor in epilepsy. Neurochem Res. 2024;49(3):533\u201347. https:\/\/doi.org\/10.1007\/s11064-023-04064-x. (in Eng).","journal-title":"Neurochem Res"},{"key":"2212_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.expneurol.2013.10.017","volume":"251","author":"DE Harlow","year":"2014","unstructured":"Harlow DE, Macklin WB. Inhibitors of myelination: ECM changes, CSPGs and PTPs. Exp Neurol. 2014;251:39\u201346. https:\/\/doi.org\/10.1016\/j.expneurol.2013.10.017.","journal-title":"Exp Neurol"},{"issue":"3","key":"2212_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.23599","volume":"72","author":"LW Lau","year":"2012","unstructured":"Lau LW, Keough MB, Haylock-Jacobs S, et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol. 2012;72(3):419\u201332. https:\/\/doi.org\/10.1002\/ana.23599.","journal-title":"Ann Neurol"},{"issue":"9","key":"2212_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/glia.22535","volume":"61","author":"JR Plemel","year":"2013","unstructured":"Plemel JR, Manesh SB, Sparling JS, et al. Myelin inhibits oligodendroglial maturation and regulates oligodendrocytic transcription factor expression. Glia. 2013;61(9):1471\u201387. https:\/\/doi.org\/10.1002\/glia.22535.","journal-title":"Glia"},{"issue":"13","key":"2212_CR31","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1101\/gad.1806309","volume":"23","author":"SPJ Fancy","year":"2009","unstructured":"Fancy SPJ, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Gene Dev. 2009;23(13):1571\u201385. https:\/\/doi.org\/10.1101\/gad.1806309.","journal-title":"Gene Dev"},{"issue":"10","key":"2212_CR32","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1523\/jneurosci.4930-10.2011","volume":"31","author":"YA Syed","year":"2011","unstructured":"Syed YA, Hand E, M\u00f6bius W, et al. Inhibition of CNS remyelination by the presence of semaphorin 3A. J Neurosci. 2011;31(10):3719\u201328. https:\/\/doi.org\/10.1523\/jneurosci.4930-10.2011.","journal-title":"J Neurosci"},{"issue":"12","key":"2212_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001743","volume":"11","author":"I Lundgaard","year":"2013","unstructured":"Lundgaard I, Luzhynskaya A, Stockley JH, et al. Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol. 2013;11(12): e1001743. https:\/\/doi.org\/10.1371\/journal.pbio.1001743.","journal-title":"PLoS Biol"},{"issue":"6183","key":"2212_CR34","doi-asserted-by":"publisher","first-page":"1252304","DOI":"10.1126\/science.1252304","volume":"344","author":"EM Gibson","year":"2014","unstructured":"Gibson EM, Purger D, Mount CW, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science. 2014;344(6183):1252304. https:\/\/doi.org\/10.1126\/science.1252304.","journal-title":"Science"},{"issue":"12","key":"2212_CR35","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1093\/brain\/awl144","volume":"129","author":"I Coman","year":"2006","unstructured":"Coman I, Aigrot MS, Seilhean D, et al. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain. 2006;129(12):3186\u201395. https:\/\/doi.org\/10.1093\/brain\/awl144.","journal-title":"Brain"},{"issue":"7399","key":"2212_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature11007","volume":"485","author":"U F\u00fcnfschilling","year":"2012","unstructured":"F\u00fcnfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517\u201321. https:\/\/doi.org\/10.1038\/nature11007.","journal-title":"Nature"},{"key":"2212_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.expneurol.2015.07.014","volume":"271","author":"CD Nuccio","year":"2015","unstructured":"Nuccio CD, Bernardo A, Cruciani C, et al. Peroxisome proliferator activated receptor-\u03b3 agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: effects on mitochondrial functions and differentiation. Exp Neurol. 2015;271:506\u201314. https:\/\/doi.org\/10.1016\/j.expneurol.2015.07.014.","journal-title":"Exp Neurol"},{"issue":"3","key":"2212_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbadis.2015.09.018","volume":"1862","author":"H Lassmann","year":"2016","unstructured":"Lassmann H, Horssen JV. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2016;1862(3):506\u201310. https:\/\/doi.org\/10.1016\/j.bbadis.2015.09.018.","journal-title":"Biochim Biophys Acta (BBA)-Mol Basis Dis"},{"issue":"1","key":"2212_CR39","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s41598-020-58709-w","volume":"10","author":"AP Robinson","year":"2020","unstructured":"Robinson AP, Zhang JZ, Titus HE, et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep. 2020;10(1):1936. https:\/\/doi.org\/10.1038\/s41598-020-58709-w. (in Eng).","journal-title":"Sci Rep"},{"key":"2212_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27200","author":"A Beaudry-Richard","year":"2025","unstructured":"Beaudry-Richard A, Abdelhak A, Saloner R, et al. Vitamin B12 levels association with functional and structural biomarkers of central nervous system injury in older adults. Ann Neurol. 2025. https:\/\/doi.org\/10.1002\/ana.27200.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"2212_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jns.2005.03.009","volume":"233","author":"A Miller","year":"2005","unstructured":"Miller A, Korem M, Almog R, et al. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. J Neurol Sci. 2005;233(1\u20132):93\u20137. https:\/\/doi.org\/10.1016\/j.jns.2005.03.009. (in Eng).","journal-title":"J Neurol Sci"},{"issue":"5","key":"2212_CR42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41593-018-0121-5","volume":"21","author":"EG Hughes","year":"2018","unstructured":"Hughes EG, Orthmann-Murphy JL, Langseth AJ, et al. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat Neurosci. 2018;21(5):696\u2013706. https:\/\/doi.org\/10.1038\/s41593-018-0121-5.","journal-title":"Nat Neurosci"},{"key":"2212_CR43","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1038\/ncomms7532","volume":"6","author":"SW Way","year":"2015","unstructured":"Way SW, Podojil JR, Clayton BL, et al. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat Commun. 2015;6:6532. https:\/\/doi.org\/10.1038\/ncomms7532. (in Eng).","journal-title":"Nat Commun"},{"issue":"19","key":"2212_CR44","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","volume":"112","author":"T Garton","year":"2024","unstructured":"Garton T, Gadani SP, Gill AJ, et al. Neurodegeneration and demyelination in multiple sclerosis. Neuron. 2024;112(19):3231\u201351. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.025.","journal-title":"Neuron"},{"key":"2212_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00801-6","author":"L Klotz","year":"2023","unstructured":"Klotz L, Antel J, Kuhlmann T. Inflammation in multiple sclerosis: consequences for remyelination and disease progression. Nat Rev Neurol. 2023. https:\/\/doi.org\/10.1038\/s41582-023-00801-6.","journal-title":"Nat Rev Neurol"},{"key":"2212_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/elife.18246","volume":"5","author":"F Mei","year":"2016","unstructured":"Mei F, Lehmann-Horn K, Shen Y-AA, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016;5: e18246. https:\/\/doi.org\/10.7554\/elife.18246.","journal-title":"Elife"},{"issue":"5","key":"2212_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12264-015-1555-3","volume":"31","author":"Z Li","year":"2015","unstructured":"Li Z, He Y, Fan S, et al. Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination. Neurosci Bull. 2015;31(5):617\u201325. https:\/\/doi.org\/10.1007\/s12264-015-1555-3.","journal-title":"Neurosci Bull"},{"issue":"5","key":"2212_CR48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2016","unstructured":"Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler J. 2016;23(5):734\u201347. https:\/\/doi.org\/10.1177\/1352458517690822.","journal-title":"Mult Scler J"},{"issue":"1\u20132","key":"2212_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jns.2012.03.009","volume":"318","author":"LJ Balcer","year":"2012","unstructured":"Balcer LJ, Galetta SL, Polman CH, et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. J Neurol Sci. 2012;318(1\u20132):119\u201324. https:\/\/doi.org\/10.1016\/j.jns.2012.03.009.","journal-title":"J Neurol Sci"},{"key":"2212_CR50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217635120","author":"E Caverzasi","year":"2023","unstructured":"Caverzasi E, Papinutto N, Cordano C, et al. MWF of the corpus callosum is a robust measure of remyelination: results from the ReBUILD trial. Proc Natl Acad Sci USA. 2023. https:\/\/doi.org\/10.1073\/pnas.2217635120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2212_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1172\/JCI183941","volume":"135","author":"J Kocot","year":"2025","unstructured":"Kocot J, Kosa P, Ashida S, et al. Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis. J Clin Invest. 2025;135(10):15. https:\/\/doi.org\/10.1172\/JCI183941.","journal-title":"J Clin Invest"},{"key":"2212_CR52","doi-asserted-by":"publisher","first-page":"1582902","DOI":"10.3389\/fncel.2025.1582902","volume":"19","author":"R Yamazaki","year":"2025","unstructured":"Yamazaki R, Ohno N. The potential of repurposing clemastine to promote remyelination. Front Cell Neurosci. 2025;19:1582902. https:\/\/doi.org\/10.3389\/fncel.2025.1582902. (in Eng).","journal-title":"Front Cell Neurosci"},{"key":"2212_CR53","doi-asserted-by":"publisher","first-page":"1279985","DOI":"10.3389\/fnmol.2023.1279985","volume":"16","author":"S Jiang","year":"2023","unstructured":"Jiang S, Wang X, Cao T, et al. Insights on therapeutic potential of clemastine in neurological disorders. Front Mol Neurosci. 2023;16:1279985. https:\/\/doi.org\/10.3389\/fnmol.2023.1279985. (in Eng).","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"2212_CR54","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/nm1664","volume":"13","author":"S Mi","year":"2007","unstructured":"Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228\u201333. https:\/\/doi.org\/10.1038\/nm1664.","journal-title":"Nat Med"},{"issue":"3","key":"2212_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nn1188","volume":"7","author":"S Mi","year":"2004","unstructured":"Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor\/p75 signaling complex. Nat Neurosci. 2004;7(3):221\u20138. https:\/\/doi.org\/10.1038\/nn1188.","journal-title":"Nat Neurosci"},{"issue":"3","key":"2212_CR56","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.21581","volume":"65","author":"S Mi","year":"2009","unstructured":"Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304\u201315. https:\/\/doi.org\/10.1002\/ana.21581.","journal-title":"Ann Neurol"},{"issue":"3","key":"2212_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1474-4422(16)30377-5","volume":"16","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189\u201399. https:\/\/doi.org\/10.1016\/s1474-4422(16)30377-5.","journal-title":"Lancet Neurol"},{"key":"2212_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.725187","volume":"15","author":"A Klistorner","year":"2021","unstructured":"Klistorner A, Graham SL. Role of Multifocal visually evoked potential as a biomarker of demyelination, spontaneous remyelination, and myelin repair in multiple sclerosis. Front Neurosci-Switz. 2021;15: 725187. https:\/\/doi.org\/10.3389\/fnins.2021.725187.","journal-title":"Front Neurosci-Switz"},{"issue":"12","key":"2212_CR59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40263-018-0575-8","volume":"32","author":"A Klistorner","year":"2018","unstructured":"Klistorner A, Chai Y, Leocani L, et al. Assessment of opicinumab in acute optic neuritis using multifocal visual evoked potential. CNS Drugs. 2018;32(12):1159\u201371. https:\/\/doi.org\/10.1007\/s40263-018-0575-8.","journal-title":"CNS Drugs"},{"key":"2212_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106185","volume":"93","author":"O Aktas","year":"2025","unstructured":"Aktas O, Ziemssen F, Ziemssen T, et al. RENEWED: a follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis. Mult Scler Relat Disord. 2025;93: 106185. https:\/\/doi.org\/10.1016\/j.msard.2024.106185.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"2212_CR61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/s1474-4422(19)30137-1","volume":"18","author":"D Cadavid","year":"2019","unstructured":"Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845\u201356. https:\/\/doi.org\/10.1016\/s1474-4422(19)30137-1.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2212_CR62","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/acn3.620","volume":"5","author":"D Cadavid","year":"2018","unstructured":"Cadavid D, Balcer L, Galetta S, et al. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neur. 2018;5(10):1154\u201362. https:\/\/doi.org\/10.1002\/acn3.620.","journal-title":"Ann Clin Transl Neur"},{"issue":"5","key":"2212_CR63","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1083\/jcb.201505119","volume":"211","author":"AGDL Fuente","year":"2015","unstructured":"Fuente AGDL, Errea O, Wijngaarden PV, et al. Vitamin D receptor\u2013retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. J Cell Biol. 2015;211(5):975\u201385. https:\/\/doi.org\/10.1083\/jcb.201505119.","journal-title":"J Cell Biol"},{"issue":"1","key":"2212_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nn.2702","volume":"14","author":"JK Huang","year":"2011","unstructured":"Huang JK, Jarjour AA, Oumesmar BN, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14(1):45\u201353. https:\/\/doi.org\/10.1038\/nn.2702.","journal-title":"Nat Neurosci"},{"issue":"9","key":"2212_CR65","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/s1474-4422(21)00179-4","volume":"20","author":"JWL Brown","year":"2021","unstructured":"Brown JWL, Cunniffe NG, Prados F, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 2021;20(9):709\u201320. https:\/\/doi.org\/10.1016\/s1474-4422(21)00179-4.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2212_CR66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1750-3639.2006.00043.x","volume":"17","author":"M Albert","year":"2007","unstructured":"Albert M, Antel J, Br\u00fcck W, et al. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 2007;17(2):129\u201338. https:\/\/doi.org\/10.1111\/j.1750-3639.2006.00043.x.","journal-title":"Brain Pathol"},{"issue":"10","key":"2212_CR67","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/acn3.51662","volume":"9","author":"JWL Brown","year":"2022","unstructured":"Brown JWL, Prados F, Altmann DR, et al. Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Ann Clin Transl Neur. 2022;9(10):1626\u201342. https:\/\/doi.org\/10.1002\/acn3.51662.","journal-title":"Ann Clin Transl Neur"},{"issue":"7","key":"2212_CR68","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acn3.51595","volume":"9","author":"CE McMurran","year":"2022","unstructured":"McMurran CE, Mukherjee T, Brown JWL, et al. Remyelination in humans due to a retinoid-X receptor agonist is age-dependent. Ann Clin Transl Neur. 2022;9(7):1090\u20134. https:\/\/doi.org\/10.1002\/acn3.51595.","journal-title":"Ann Clin Transl Neur"},{"issue":"12","key":"2212_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189380","volume":"12","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhen W, Guo T, et al. Histamine receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS ONE. 2017;12(12): e0189380. https:\/\/doi.org\/10.1371\/journal.pone.0189380.","journal-title":"PLoS ONE"},{"issue":"2","key":"2212_CR70","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00415-016-8341-7","volume":"264","author":"CJ Schwartzbach","year":"2017","unstructured":"Schwartzbach CJ, Grove RA, Brown R, et al. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol. 2017;264(2):304\u201315. https:\/\/doi.org\/10.1007\/s00415-016-8341-7.","journal-title":"J Neurol"},{"issue":"9\u201310","key":"2212_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.drudis.2009.02.011","volume":"14","author":"MJ Gemkow","year":"2009","unstructured":"Gemkow MJ, Davenport AJ, Harich S, et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today. 2009;14(9\u201310):509\u201315. https:\/\/doi.org\/10.1016\/j.drudis.2009.02.011.","journal-title":"Drug Discov Today"},{"issue":"24","key":"2212_CR72","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.1073\/pnas.0702291104","volume":"104","author":"C Teuscher","year":"2007","unstructured":"Teuscher C, Subramanian M, Noubade R, et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci USA. 2007;104(24):10146\u201351. https:\/\/doi.org\/10.1073\/pnas.0702291104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2212_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.576974","volume":"334","author":"MW Koch","year":"2019","unstructured":"Koch MW, Liu W-Q, Camara-Lemarroy C, et al. Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. J Neuroimmunol. 2019;334: 576974. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.576974.","journal-title":"J Neuroimmunol"},{"issue":"8","key":"2212_CR74","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1523\/jneurosci.4441-06.2007","volume":"27","author":"C Gregg","year":"2007","unstructured":"Gregg C, Shikar V, Larsen P, et al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci. 2007;27(8):1812\u201323. https:\/\/doi.org\/10.1523\/jneurosci.4441-06.2007.","journal-title":"J Neurosci"},{"issue":"1","key":"2212_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12974-015-0278-8","volume":"12","author":"S Zhornitsky","year":"2015","unstructured":"Zhornitsky S, Johnson TA, Metz LM, et al. Prolactin in combination with interferon-\u03b2 reduces disease severity in an animal model of multiple sclerosis. J Neuroinflammation. 2015;12(1):55. https:\/\/doi.org\/10.1186\/s12974-015-0278-8.","journal-title":"J Neuroinflammation"},{"key":"2212_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105525","volume":"85","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu W-Q, Hosseinpour Z, et al. Feasibility study to assess lesion repair in relapsing-remitting multiple sclerosis: a randomized controlled pilot clinical trial of domperidone add-on treatment. Mult Scler Relat Disord. 2024;85: 105525. https:\/\/doi.org\/10.1016\/j.msard.2024.105525.","journal-title":"Mult Scler Relat Disord"},{"issue":"18","key":"2212_CR77","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1212\/wnl.0000000000011863","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch MW, Sage K, Kaur S, et al. Repurposing domperidone in secondary progressive multiple sclerosis: a Simon 2-stage phase 2 futility trial. Neurology. 2021;96(18):e2313\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000011863.","journal-title":"Neurology"},{"issue":"1","key":"2212_CR78","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0165-3806(88)90157-5","volume":"471","author":"FA Tansey","year":"1988","unstructured":"Tansey FA, Cammer W. Acetyl-CoA carboxylase in rat brain. I. Activities in homogenates and isolated fractions. Brain Res. 1988;471(1):123\u201330. https:\/\/doi.org\/10.1016\/0165-3806(88)90157-5. (in Eng).","journal-title":"Brain Res"},{"issue":"13","key":"2212_CR79","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/1352458516667568","volume":"22","author":"A Tourbah","year":"2016","unstructured":"Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler J. 2016;22(13):1719\u201331. https:\/\/doi.org\/10.1177\/1352458516667568.","journal-title":"Mult Scler J"},{"issue":"2","key":"2212_CR80","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.msard.2015.01.005","volume":"4","author":"F Sedel","year":"2015","unstructured":"Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159\u201369. https:\/\/doi.org\/10.1016\/j.msard.2015.01.005.","journal-title":"Mult Scler Relat Disord"},{"key":"2212_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30347-1","author":"BAC Cree","year":"2020","unstructured":"Cree BAC, Cutter G, Wolinsky JS, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020. https:\/\/doi.org\/10.1016\/S1474-4422(20)30347-1.","journal-title":"Lancet Neurol"},{"issue":"7","key":"2212_CR82","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40263-018-0528-2","volume":"32","author":"A Tourbah","year":"2018","unstructured":"Tourbah A, Gout O, Vighetto A, et al. MD1003 (high-dose pharmaceutical-grade biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study. CNS Drugs. 2018;32(7):661\u201372. https:\/\/doi.org\/10.1007\/s40263-018-0528-2.","journal-title":"CNS Drugs"},{"issue":"7","key":"2212_CR83","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.4103\/1673-5374.361542","volume":"18","author":"F Szepanowski","year":"2023","unstructured":"Szepanowski F, Steubing RD, G\u00fcng\u00f6r C, et al. High-dose biotin neither fosters remyelination nor stimulates malonyl coenzyme A synthesis in the regenerating nerve. Neural Regen Res. 2023;18(7):1623\u20134. https:\/\/doi.org\/10.4103\/1673-5374.361542. (in Eng).","journal-title":"Neural Regen Res"},{"issue":"2","key":"2212_CR84","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jphotobiol.2005.05.010","volume":"81","author":"X Huang","year":"2005","unstructured":"Huang X, El-Sayed IH, Yi X, et al. Gold nanoparticles: catalyst for the oxidation of NADH to NAD(+). J Photochem Photobiol B. 2005;81(2):76\u201383. https:\/\/doi.org\/10.1016\/j.jphotobiol.2005.05.010. (in Eng).","journal-title":"J Photochem Photobiol B"},{"issue":"17_supplement_2","key":"2212_CR85","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1212\/WNL.0000000000203858","volume":"100","author":"M Barnett","year":"2023","unstructured":"Barnett M, Beadnall H, Klistorner A, et al. VISIONARY-MS top-line results: a phase 2, randomized, double-blind, parallel group, placebo-controlled study to assess the safety and efficacy of CNM-Au8, a catalytically active gold nanocrystal suspension in relapsing multiple sclerosis (PL5.005). Neurology. 2023;100(17_supplement_2):4273. https:\/\/doi.org\/10.1212\/WNL.0000000000203858.","journal-title":"Neurology"},{"key":"2212_CR86","doi-asserted-by":"publisher","unstructured":"ECTRIMS 2024 Late breaking poster, Mult Scler J. 2024;30(3_suppl): 1148-1211. https:\/\/doi.org\/10.1177\/13524585241269220.","DOI":"10.1177\/13524585241269220"},{"key":"2212_CR87","unstructured":"Greenberg BM, Beadnall H, Sergott R et al. Physiologic and anatomical evidence of neuronal repair and remyelination from the long-term open label extension of the phase 2 VISIONARY-MS trial, presented at the American Academy of Neurology Annual Meeting, San Diego, CA, 2025."},{"key":"2212_CR88","doi-asserted-by":"publisher","first-page":"104375","DOI":"10.1016\/j.msard.2022.104375","volume":"68","author":"TA Fuchs","year":"2022","unstructured":"Fuchs TA, Gillies J, Jaworski MG, et al. Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset. Mult Scler Relat Disord. 2022;68:104375. https:\/\/doi.org\/10.1016\/j.msard.2022.104375.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"2212_CR89","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1523\/jneurosci.1530-18.2019","volume":"39","author":"KA Rankin","year":"2019","unstructured":"Rankin KA, Mei F, Kim K, et al. Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors. J Neurosci. 2019;39(12):2184\u201394. https:\/\/doi.org\/10.1523\/jneurosci.1530-18.2019.","journal-title":"J Neurosci"},{"key":"2212_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107333","volume":"134","author":"A Nylander","year":"2023","unstructured":"Nylander A, Anderson A, Rowles W, et al. Re-WRAP (remyelination for women at risk of axonal loss and progression): a phase II randomized placebo-controlled delayed-start trial of bazedoxifene for myelin repair in multiple sclerosis. Contemp Clin Trials. 2023;134: 107333. https:\/\/doi.org\/10.1016\/j.cct.2023.107333. (in Eng).","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"2212_CR91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0361-9230(91)90025-F","volume":"26","author":"MJ Pontecorvo","year":"1991","unstructured":"Pontecorvo MJ, Karbon EW, Goode S, et al. Possible cerebroprotective and in vivo NMDA antagonist activities of sigma agents. Brain Res Bull. 1991;26(3):461\u20135. https:\/\/doi.org\/10.1016\/0361-9230(91)90025-F.","journal-title":"Brain Res Bull"},{"issue":"18","key":"2212_CR92","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1073\/pnas.93.18.9887","volume":"93","author":"C Demerens","year":"1996","unstructured":"Demerens C, Stankoff B, Logak M, et al. Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci USA. 1996;93(18):9887\u201392. https:\/\/doi.org\/10.1073\/pnas.93.18.9887.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7718","key":"2212_CR93","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41586-018-0360-3","volume":"560","author":"Z Hubler","year":"2018","unstructured":"Hubler Z, Allimuthu D, Bederman I, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018;560(7718):372\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0360-3. (in Eng).","journal-title":"Nature"},{"issue":"32","key":"2212_CR94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2407974121","volume":"121","author":"MM Poon","year":"2024","unstructured":"Poon MM, Lorrain KI, Stebbins KJ, et al. Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis. Proc Natl Acad Sci USA. 2024;121(32): e2407974121. https:\/\/doi.org\/10.1073\/pnas.2407974121. (in Eng).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2212_CR95","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jneuroim.2003.11.004","volume":"146","author":"KM Palaszynski","year":"2004","unstructured":"Palaszynski KM, Loo KK, Ashouri JF, et al. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol. 2004;146(1):144\u201352. https:\/\/doi.org\/10.1016\/j.jneuroim.2003.11.004.","journal-title":"J Neuroimmunol"},{"issue":"Pt 1","key":"2212_CR96","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/brain\/aws284","volume":"136","author":"R Hussain","year":"2013","unstructured":"Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136(Pt 1):132\u201346. https:\/\/doi.org\/10.1093\/brain\/aws284. (in Eng).","journal-title":"Brain"},{"issue":"6","key":"2212_CR97","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","volume":"29","author":"Y Wang","year":"2019","unstructured":"Wang Y, An H, Liu T, et al. Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. 2019;29(6):1511-1523.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.09.070. (in Eng).","journal-title":"Cell Rep"},{"issue":"4","key":"2212_CR98","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","volume":"25","author":"B Neumann","year":"2019","unstructured":"Neumann B, Baror R, Zhao C, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25(4):473-485.e8. https:\/\/doi.org\/10.1016\/j.stem.2019.08.015. (in Eng).","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2212_CR99","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ajpath.2013.04.030","volume":"183","author":"AS Paintlia","year":"2013","unstructured":"Paintlia AS, Paintlia MK, Mohan S, et al. AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model. Am J Pathol. 2013;183(2):526\u201341. https:\/\/doi.org\/10.1016\/j.ajpath.2013.04.030. (in Eng).","journal-title":"Am J Pathol"},{"key":"2212_CR100","doi-asserted-by":"publisher","first-page":"1254303","DOI":"10.3389\/fncel.2023.1254303","volume":"17","author":"M Narine","year":"2023","unstructured":"Narine M, Azmi MA, Umali M, et al. The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation. Front Cell Neurosci. 2023;17:1254303. https:\/\/doi.org\/10.3389\/fncel.2023.1254303. (in Eng).","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"2212_CR101","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s13311-017-0577-0","volume":"14","author":"RM Bove","year":"2017","unstructured":"Bove RM, Green AJ. Remyelinating pharmacotherapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):894\u2013904. https:\/\/doi.org\/10.1007\/s13311-017-0577-0.","journal-title":"Neurotherapeutics"},{"issue":"16","key":"2212_CR102","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/cells13161326","volume":"13","author":"AIAA Jaf","year":"2024","unstructured":"Jaf AIAA, Peria S, Fabiano T, et al. Remyelinating drugs at a crossroad: how to improve clinical efficacy and drug screenings. Cells. 2024;13(16):1326. https:\/\/doi.org\/10.3390\/cells13161326.","journal-title":"Cells"},{"key":"2212_CR103","doi-asserted-by":"publisher","unstructured":"Kocot J, Kosa P, Ashida S et al. Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis, medRxiv, p. 2024.04.09.24305506, 2024, https:\/\/doi.org\/10.1101\/2024.04.09.24305506.","DOI":"10.1101\/2024.04.09.24305506"},{"issue":"2","key":"2212_CR104","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001126","volume":"9","author":"JS Graves","year":"2021","unstructured":"Graves JS, Oertel FC, Walt AVd, et al. Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders. Neurol Neuroimmunol Neuroinflamm. 2021;9(2): e1126. https:\/\/doi.org\/10.1212\/nxi.0000000000001126.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"2212_CR105","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awu335","volume":"138","author":"LJ Balcer","year":"2015","unstructured":"Balcer LJ, Miller DH, Reingold SC, et al. Vision and vision-related outcome measures in multiple sclerosis. Brain. 2015;138(1):11\u201327. https:\/\/doi.org\/10.1093\/brain\/awu335.","journal-title":"Brain"},{"issue":"13","key":"2212_CR106","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/wnl.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):e1854\u201367. https:\/\/doi.org\/10.1212\/wnl.0000000000010376. (in Eng).","journal-title":"Neurology"},{"issue":"12","key":"2212_CR107","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","volume":"80","author":"A Abdelhak","year":"2023","unstructured":"Abdelhak A, Benkert P, Schaedelin S, et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 2023;80(12):1317\u201325. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3997.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2212_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076651","volume":"14","author":"S Hof","year":"2024","unstructured":"Hof S, Rijn LJv, Uitdehaag BMJ, et al. Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE). Br Med J Open. 2024;14(1): e076651. https:\/\/doi.org\/10.1136\/bmjopen-2023-076651.","journal-title":"Br Med J Open"},{"issue":"2","key":"2212_CR109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/wno.0000000000002149","volume":"44","author":"LR Zuroff","year":"2024","unstructured":"Zuroff LR, Green AJ. The study of remyelinating therapies in multiple sclerosis: visual outcomes as a window into repair. J Neuroophthalmol. 2024;44(2):143\u201356. https:\/\/doi.org\/10.1097\/wno.0000000000002149. (in Eng).","journal-title":"J Neuroophthalmol"},{"issue":"11","key":"2212_CR110","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/brain\/awac207","volume":"145","author":"C Cordano","year":"2022","unstructured":"Cordano C, Sin JH, Timmons G, et al. Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy. Brain. 2022;145(11):3943\u201352. https:\/\/doi.org\/10.1093\/brain\/awac207.","journal-title":"Brain"},{"issue":"3","key":"2212_CR111","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200092","volume":"10","author":"FC Oertel","year":"2023","unstructured":"Oertel FC, Kr\u00e4mer J, Motamedi S, et al. Visually evoked potential as prognostic biomarker for neuroaxonal damage in multiple sclerosis from a multicenter longitudinal cohort. Neurology Neuroimmunol Neuroinflamm. 2023;10(3): e200092. https:\/\/doi.org\/10.1212\/nxi.0000000000200092.","journal-title":"Neurology Neuroimmunol Neuroinflamm"},{"issue":"9","key":"2212_CR112","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/brain\/awq146","volume":"133","author":"APD Henderson","year":"2010","unstructured":"Henderson APD, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. 2010;133(9):2592\u2013602. https:\/\/doi.org\/10.1093\/brain\/awq146.","journal-title":"Brain"},{"issue":"11","key":"2212_CR113","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1093\/brain\/124.11.2162","volume":"124","author":"P Fuhr","year":"2001","unstructured":"Fuhr P, Borggrefe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. Brain. 2001;124(11):2162\u20138. https:\/\/doi.org\/10.1093\/brain\/124.11.2162.","journal-title":"Brain"},{"issue":"3","key":"2212_CR114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00004691-199405000-00004","volume":"11","author":"ON Markand","year":"1994","unstructured":"Markand ON. Brainstem auditory evoked potentials. J Clin Neurophysiol. 1994;11(3):319\u201342. https:\/\/doi.org\/10.1097\/00004691-199405000-00004. (in Eng).","journal-title":"J Clin Neurophysiol"},{"key":"2212_CR115","doi-asserted-by":"publisher","first-page":"103393","DOI":"10.1016\/j.mcn.2019.103393","volume":"99","author":"BJ Farley","year":"2019","unstructured":"Farley BJ, Morozova E, Dion J, et al. Evoked potentials as a translatable biomarker to track functional remyelination. Mol Cell Neurosci. 2019;99:103393. https:\/\/doi.org\/10.1016\/j.mcn.2019.103393.","journal-title":"Mol Cell Neurosci"},{"key":"2212_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac436","author":"CWJvd Weijden","year":"2022","unstructured":"Weijden CWJvd, Biondetti E, Gutmann IW, et al. Quantitative myelin imaging with MRI and PET: an overview of techniques and their validation status. Brain. 2022. https:\/\/doi.org\/10.1093\/brain\/awac436.","journal-title":"Brain"},{"key":"2212_CR117","doi-asserted-by":"publisher","first-page":"117561","DOI":"10.1016\/j.neuroimage.2020.117561","volume":"226","author":"CWJvd Weijden","year":"2021","unstructured":"Weijden CWJvd, Garc\u00eda DV, Borra RJH, et al. Myelin quantification with MRI: a systematic review of accuracy and reproducibility. Neuroimage. 2021;226:117561. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117561.","journal-title":"Neuroimage"},{"issue":"3","key":"2212_CR118","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.20202","volume":"56","author":"K Schmierer","year":"2004","unstructured":"Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407\u201315. https:\/\/doi.org\/10.1002\/ana.20202.","journal-title":"Ann Neurol"},{"key":"2212_CR119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mri.2020.03.010","volume":"70","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wen B, Chen T, et al. A comparison study of inhomogeneous magnetization transfer (ihMT) and magnetization transfer (MT) in multiple sclerosis based on whole brain acquisition at 3.0 T. Magn Reson Imaging. 2020;70:43\u20139. https:\/\/doi.org\/10.1016\/j.mri.2020.03.010.","journal-title":"Magn Reson Imaging"},{"issue":"5","key":"2212_CR120","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bpa.12645","volume":"28","author":"C Laule","year":"2018","unstructured":"Laule C, Moore GRW. Myelin water imaging to detect demyelination and remyelination and its validation in pathology. Brain Pathol. 2018;28(5):750\u201364. https:\/\/doi.org\/10.1111\/bpa.12645.","journal-title":"Brain Pathol"},{"issue":"3","key":"2212_CR121","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00415-004-0306-6","volume":"251","author":"C Laule","year":"2004","unstructured":"Laule C, Vavasour IM, Moore GRW, et al. Water content and myelin water fraction in multiple sclerosis. J Neurol. 2004;251(3):284\u201393. https:\/\/doi.org\/10.1007\/s00415-004-0306-6.","journal-title":"J Neurol"},{"issue":"6","key":"2212_CR122","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.21037\/qims-20-541","volume":"10","author":"Y-J Ma","year":"2020","unstructured":"Ma Y-J, Jang H, Chang EY, et al. Ultrashort echo time (UTE) magnetic resonance imaging of myelin: technical developments and challenges. Quant Imaging Med Surg. 2020;10(6):1186\u2013203. https:\/\/doi.org\/10.21037\/qims-20-541.","journal-title":"Quant Imaging Med Surg"},{"key":"2212_CR123","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuroimage.2016.05.012","volume":"136","author":"V Sheth","year":"2016","unstructured":"Sheth V, Shao H, Chen J, et al. Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: phantom, specimen, volunteer and multiple sclerosis patient studies. Neuroimage. 2016;136:37\u201344. https:\/\/doi.org\/10.1016\/j.neuroimage.2016.05.012.","journal-title":"Neuroimage"},{"issue":"8","key":"2212_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3727","volume":"30","author":"V Wiggermann","year":"2017","unstructured":"Wiggermann V, Hametner S, Hern\u00e1ndez-Torres E, et al. Susceptibility-sensitive MRI of multiple sclerosis lesions and the impact of normal-appearing white matter changes. NMR Biomed. 2017;30(8): e3727. https:\/\/doi.org\/10.1002\/nbm.3727.","journal-title":"NMR Biomed"},{"issue":"10","key":"2212_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4326","volume":"33","author":"YJ Ma","year":"2020","unstructured":"Ma YJ, Searleman AC, Jang H, et al. Volumetric imaging of myelin in vivo using 3D inversion recovery-prepared ultrashort echo time cones magnetic resonance imaging. NMR Biomed. 2020;33(10): e4326. https:\/\/doi.org\/10.1002\/nbm.4326.","journal-title":"NMR Biomed"},{"issue":"5","key":"2212_CR126","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ana.24620","volume":"79","author":"B Bodini","year":"2016","unstructured":"Bodini B, Veronese M, Garc\u00eda-Lorenzo D, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol. 2016;79(5):726\u201338. https:\/\/doi.org\/10.1002\/ana.24620.","journal-title":"Ann Neurol"},{"issue":"2","key":"2212_CR127","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00259-019-04516-z","volume":"47","author":"S Auvity","year":"2020","unstructured":"Auvity S, Tonietto M, Caill\u00e9 F, et al. Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol I. 2020;47(2):490\u2013501. https:\/\/doi.org\/10.1007\/s00259-019-04516-z.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"5","key":"2212_CR128","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders\u2014towards clinical application. Nat Rev Neurol. 2024;20(5):269\u201387. https:\/\/doi.org\/10.1038\/s41582-024-00955-x.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2212_CR129","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z. (in Eng).","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2212_CR130","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/wnl.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315. https:\/\/doi.org\/10.1212\/wnl.0000000000007032. (in Eng).","journal-title":"Neurology"},{"key":"2212_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852563","volume":"13","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Arnold DL, Alvarez E, et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front Immunol. 2022;13: 852563. https:\/\/doi.org\/10.3389\/fimmu.2022.852563. (in Eng).","journal-title":"Front Immunol"},{"key":"2212_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662","volume":"93","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Thanei GA, Harp C, et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023;93: 104662. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662. (in Eng).","journal-title":"EBioMedicine"},{"issue":"24","key":"2212_CR133","doi-asserted-by":"publisher","first-page":"25729","DOI":"10.18632\/aging.203790","volume":"13","author":"M Koini","year":"2021","unstructured":"Koini M, Pirpamer L, Hofer E, et al. Factors influencing serum neurofilament light chain levels in normal aging. Aging (Albany NY). 2021;13(24):25729\u201338. https:\/\/doi.org\/10.18632\/aging.203790. (in Eng).","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"2212_CR134","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.26446","volume":"92","author":"KC Fitzgerald","year":"2022","unstructured":"Fitzgerald KC, Sotirchos ES, Smith MD, et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol. 2022;92(4):688\u201398. https:\/\/doi.org\/10.1002\/ana.26446. (in Eng).","journal-title":"Ann Neurol"},{"issue":"11","key":"2212_CR135","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u20131444. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"issue":"7","key":"2212_CR136","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963\u201373. https:\/\/doi.org\/10.1177\/1352458517709619. (in Eng).","journal-title":"Mult Scler"},{"issue":"4","key":"2212_CR137","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BA Cree","year":"2016","unstructured":"Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499\u2013510. https:\/\/doi.org\/10.1002\/ana.24747. (in Eng).","journal-title":"Ann Neurol"},{"issue":"5","key":"2212_CR138","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(5):871\u201382. https:\/\/doi.org\/10.1093\/brain\/122.5.871.","journal-title":"Brain"},{"issue":"8","key":"2212_CR139","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/1352458509106212","volume":"15","author":"RA Rudick","year":"2009","unstructured":"Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009;15(8):984\u201397. https:\/\/doi.org\/10.1177\/1352458509106212.","journal-title":"Mult Scler"},{"issue":"4","key":"2212_CR140","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/135245850000600411","volume":"6","author":"M Kaufman","year":"2000","unstructured":"Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler. 2000;6(4):286\u201390. https:\/\/doi.org\/10.1177\/135245850000600411.","journal-title":"Mult Scler"},{"issue":"5","key":"2212_CR141","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1177\/1352458506070768","volume":"12","author":"JJ Kragt","year":"2006","unstructured":"Kragt JJ, Linden FAHvd, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler. 2006;12(5):594\u20138. https:\/\/doi.org\/10.1177\/1352458506070768.","journal-title":"Mult Scler"},{"issue":"7","key":"2212_CR142","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-008-0767-0","volume":"255","author":"C Ytterberg","year":"2008","unstructured":"Ytterberg C, Johansson S, Andersson M, et al. Variations in functioning and disability in multiple sclerosis. J Neurol. 2008;255(7):967\u201373. https:\/\/doi.org\/10.1007\/s00415-008-0767-0.","journal-title":"J Neurol"},{"issue":"4","key":"2212_CR143","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/135245859900500409","volume":"5","author":"JS Fischer","year":"1999","unstructured":"Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4):244\u201350. https:\/\/doi.org\/10.1177\/135245859900500409. (in Eng).","journal-title":"Mult Scler"},{"issue":"6","key":"2212_CR144","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/archneur.58.6.961","volume":"58","author":"JA Cohen","year":"2001","unstructured":"Cohen JA, Cutter GR, Fischer JS, et al. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58(6):961\u20137. https:\/\/doi.org\/10.1001\/archneur.58.6.961.","journal-title":"Arch Neurol"},{"issue":"1","key":"2212_CR145","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","volume":"21","author":"TN Tombaugh","year":"2006","unstructured":"Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol. 2006;21(1):53\u201376. https:\/\/doi.org\/10.1016\/j.acn.2005.07.006.","journal-title":"Arch Clin Neuropsychol"},{"issue":"21","key":"2212_CR146","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","volume":"81","author":"MD Goldman","year":"2013","unstructured":"Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS. Neurology. 2013;81(21):1856\u201363. https:\/\/doi.org\/10.1212\/01.wnl.0000436065.97642.d2.","journal-title":"Neurology"},{"issue":"2","key":"2212_CR147","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458509354552","volume":"16","author":"AS Drake","year":"2010","unstructured":"Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010;16(2):228\u201337. https:\/\/doi.org\/10.1177\/1352458509354552.","journal-title":"Mult Scler"},{"key":"2212_CR148","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008519","author":"MD Goldman","year":"2019","unstructured":"Goldman MD, LaRocca NG, Rudick RA, et al. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology. 2019. https:\/\/doi.org\/10.1212\/wnl.0000000000008519.","journal-title":"Neurology"},{"issue":"3","key":"2212_CR149","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/13524585221143726","volume":"29","author":"VJ Block","year":"2023","unstructured":"Block VJ, Cheng S, Juwono J, et al. Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. Mult Scler. 2023;29(3):363\u201373. https:\/\/doi.org\/10.1177\/13524585221143726. (in Eng).","journal-title":"Mult Scler"},{"issue":"3","key":"2212_CR150","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0570","volume":"2","author":"VJ Block","year":"2019","unstructured":"Block VJ, Bove R, Zhao C, et al. Association of continuous assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. JAMA Netw Open. 2019;2(3): e190570. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0570. (in Eng).","journal-title":"JAMA Netw Open"},{"key":"2212_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.860008","volume":"13","author":"VJ Block","year":"2022","unstructured":"Block VJ, Waliman M, Xie Z, et al. Making every step count: minute-by-minute characterization of step counts augments remote activity monitoring in people with multiple sclerosis. Front Neurol. 2022;13: 860008. https:\/\/doi.org\/10.3389\/fneur.2022.860008. (in Eng).","journal-title":"Front Neurol"},{"key":"2212_CR152","doi-asserted-by":"crossref","unstructured":"Nylander AAA, Rowles W, Hsu S, Lazar A, Mayoral SR, Pease-Raissi SE, Green A, Bove R. Re-WRAP (remyelination for women at risk of axonal loss and progression): a phase ii randomized placebo-controlled delayed start trial of bazedoxifene for myelin repair in multiple sclerosis, presented at the ECTRIMS 2023, 2023.","DOI":"10.1016\/j.cct.2023.107333"},{"issue":"5","key":"2212_CR153","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1177\/1352458520930371","volume":"27","author":"R Bove","year":"2021","unstructured":"Bove R, Rowles W, Zhao C, et al. A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: a pilot study. Mult Scler. 2021;27(5):778\u201389. https:\/\/doi.org\/10.1177\/1352458520930371.","journal-title":"Mult Scler"},{"issue":"12","key":"2212_CR154","doi-asserted-by":"publisher","DOI":"10.2196\/25748","volume":"23","author":"WY Hsu","year":"2021","unstructured":"Hsu WY, Rowles W, Anguera JA, et al. Assessing cognitive function in multiple sclerosis with digital tools: observational study. J Med Internet Res. 2021;23(12): e25748. https:\/\/doi.org\/10.2196\/25748. (in Eng).","journal-title":"J Med Internet Res"},{"issue":"1","key":"2212_CR155","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41467-025-56092-6","volume":"16","author":"G Della-Flora Nunes","year":"2025","unstructured":"Della-Flora Nunes G, Osso LA, Haynes JA, et al. Incomplete remyelination via therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function. Nat Commun. 2025;16(1):732. https:\/\/doi.org\/10.1038\/s41467-025-56092-6.","journal-title":"Nat Commun"},{"issue":"12","key":"2212_CR156","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/s1474-4422(20)30347-1","volume":"19","author":"BAC Cree","year":"2020","unstructured":"Cree BAC, Cutter G, Wolinsky JS, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):988\u201397. https:\/\/doi.org\/10.1016\/s1474-4422(20)30347-1.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2212_CR157","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","volume":"67","author":"LS Talman","year":"2010","unstructured":"Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. 2010;67(6):749\u201360. https:\/\/doi.org\/10.1002\/ana.22005.","journal-title":"Ann Neurol"},{"key":"2212_CR158","doi-asserted-by":"publisher","unstructured":"Strober L, DeLuca J, Benedict RH, et al. Multiple Sclerosis\nOutcome Assessments Consortium (MSOAC). Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in\nmultiple sclerosis. Mult Scler. 2019;25(13):1781\u201390. https:\/\/doi.org\/10.1177\/1352458518808204. Epub 2018 Oct 18. PMID: 30334474;\nPMCID: PMC6826875","DOI":"10.1177\/1352458518808204"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02212-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:27Z","timestamp":1761715887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02212-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":158,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02212-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Leah Zuroff has received speaking fees from EMD Serono. Vista Farkhondeh has no relevant disclosures. Riley Bove has received research support from Biogen, Eli Lilly, Novartis, and Roche Genentech. She has received personal fees for advisory boards and consulting from Alexion, Amgen, Cadenza, EMD Serono, Sanofi, and TG Therapeutics. Ari Green reports grants from the NINDS, NMSS, All May See, Westridge Foundation, and other financial relationships for activities as expert witness, associate editor, advisory board or steering committee participation, and endpoint adjudication from\n                      JAMA Neurology\n                      , Roche, Pipeline Pharmaceuticals, and Cognito Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No original data were presented in the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Leah Zuroff and Ari Green conceived of the idea for the article. Leah Zuroff, Vista Farkhondeh, and Riley Bove performed relevant literature search and drafted the manuscript and figures. Riley Bove and Ari Green critically revised the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}